Programme
Programme
Day 2: From innovation to implementation
Day 2: From innovation to implementation
The second day focuses on how psychedelic-assisted therapies move from scientific research into clinical practice. It explores international implementation models, regulatory frameworks, and the next steps for advancing psychedelic-assisted therapies in Estonia.
Simultaneous interpretation into English will be provided for all presentations delivered in Estonian.
09:30–09:35
·
Opening remarks
09:35–10:20
Psychedelic Therapy – Effects, Neuromechanisms, and Clinical Implementation Routes
This talk focuses on how psychedelic therapies such as psilocybin, DMT and ketamine can be integrated into public healthcare systems. Drawing on research and clinical programmes within the UK National Health Service (NHS), it explores practical models for implementation, alongside the latest findings on the therapeutic mechanisms and clinical effects of these treatments.
Dr. David Erritzoe, MD, PhD, MRCPsych
Clinical Associate Professor in Psychopharmacology and Psychiatry, Director of the Centre for Psychedelic Research & CIPPRes Clinic (Imperial College London)
09:35–10:20
Psychedelic Therapy – Effects, Neuromechanisms, and Clinical Implementation Routes
This talk focuses on how psychedelic therapies such as psilocybin, DMT and ketamine can be integrated into public healthcare systems. Drawing on research and clinical programmes within the UK National Health Service (NHS), it explores practical models for implementation, alongside the latest findings on the therapeutic mechanisms and clinical effects of these treatments.
Dr. David Erritzoe, MD, PhD, MRCPsych
Clinical Associate Professor in Psychopharmacology and Psychiatry, Director of the Centre for Psychedelic Research & CIPPRes Clinic (Imperial College London)
09:35–10:20
Psychedelic Therapy – Effects, Neuromechanisms, and Clinical Implementation Routes
This talk focuses on how psychedelic therapies such as psilocybin, DMT and ketamine can be integrated into public healthcare systems. Drawing on research and clinical programmes within the UK National Health Service (NHS), it explores practical models for implementation, alongside the latest findings on the therapeutic mechanisms and clinical effects of these treatments.
Dr. David Erritzoe, MD, PhD, MRCPsych
Clinical Associate Professor in Psychopharmacology and Psychiatry, Director of the Centre for Psychedelic Research & CIPPRes Clinic (Imperial College London)
10:20–11:05
From Clinical Evidence to Compassionate Use: Psilocybin Therapy for Treatment-Resistant Depression in Germany
This talk presents key findings from the largest academically initiated clinical trial of psilocybin to date, involving 144 patients with treatment-resistant depression. It explores how the study led to the European Union’s first compassionate use programme for a psychedelic, approved in Germany in 2025, and discusses the challenges and early experiences of translating clinical evidence into real-world practice.
Prof. Dr. med. Gerhard Gründer
Professor of Psychiatry and Head of the Department of Molecular Neuroimaging (Central Institute of Mental Health in Mannheim); Medical Director (OVID Clinic Berlin)
10:20–11:05
From Clinical Evidence to Compassionate Use: Psilocybin Therapy for Treatment-Resistant Depression in Germany
This talk presents key findings from the largest academically initiated clinical trial of psilocybin to date, involving 144 patients with treatment-resistant depression. It explores how the study led to the European Union’s first compassionate use programme for a psychedelic, approved in Germany in 2025, and discusses the challenges and early experiences of translating clinical evidence into real-world practice.
Prof. Dr. med. Gerhard Gründer
Professor of Psychiatry and Head of the Department of Molecular Neuroimaging (Central Institute of Mental Health in Mannheim); Medical Director (OVID Clinic Berlin)
10:20–11:05
From Clinical Evidence to Compassionate Use: Psilocybin Therapy for Treatment-Resistant Depression in Germany
This talk presents key findings from the largest academically initiated clinical trial of psilocybin to date, involving 144 patients with treatment-resistant depression. It explores how the study led to the European Union’s first compassionate use programme for a psychedelic, approved in Germany in 2025, and discusses the challenges and early experiences of translating clinical evidence into real-world practice.
Prof. Dr. med. Gerhard Gründer
Professor of Psychiatry and Head of the Department of Molecular Neuroimaging (Central Institute of Mental Health in Mannheim); Medical Director (OVID Clinic Berlin)
11:05–11:35
·
Coffee break
11:35–12:20
National Implementation of Ketamine Treatment for Depression in Norway
In the Fall of 2025, Norway became the first country in the world to reimburse racemic ketamine for depression on a national level. This is the story of how and why it happened, and what other countries can learn from the process of building the infrastructure for psychedelic-assisted therapies.
Lowan Stewart, MD
Medical Director (Axonklinikken); Medical Research Advisor (PsykForsk, DPS Nordre Østfold)
11:35–12:20
National Implementation of Ketamine Treatment for Depression in Norway
In the Fall of 2025, Norway became the first country in the world to reimburse racemic ketamine for depression on a national level. This is the story of how and why it happened, and what other countries can learn from the process of building the infrastructure for psychedelic-assisted therapies.
Lowan Stewart, MD
Medical Director (Axonklinikken); Medical Research Advisor (PsykForsk, DPS Nordre Østfold)
11:35–12:20
National Implementation of Ketamine Treatment for Depression in Norway
In the Fall of 2025, Norway became the first country in the world to reimburse racemic ketamine for depression on a national level. This is the story of how and why it happened, and what other countries can learn from the process of building the infrastructure for psychedelic-assisted therapies.
Lowan Stewart, MD
Medical Director (Axonklinikken); Medical Research Advisor (PsykForsk, DPS Nordre Østfold)
12.20-13.05
The Swiss Special Access Program for Psychedelic-Assisted Therapy: Clinical Practice, Challenges, and Future Perspectives
This session explores Switzerland’s pioneering limited medical use programme for psychedelic-assisted therapy, including LSD, psilocybin and MDMA. It examines the regulatory framework, clinical experience, patient selection and ethical considerations, as well as current developments and future challenges for policy and practice.
Helena Aicher, PhD
Psychotherapist (Psychiatric Clinic of the University of Zurich); Postdoctoral researcher (University of Zurich)
12.20-13.05
The Swiss Special Access Program for Psychedelic-Assisted Therapy: Clinical Practice, Challenges, and Future Perspectives
This session explores Switzerland’s pioneering limited medical use programme for psychedelic-assisted therapy, including LSD, psilocybin and MDMA. It examines the regulatory framework, clinical experience, patient selection and ethical considerations, as well as current developments and future challenges for policy and practice.
Helena Aicher, PhD
Psychotherapist (Psychiatric Clinic of the University of Zurich); Postdoctoral researcher (University of Zurich)
12.20-13.05
The Swiss Special Access Program for Psychedelic-Assisted Therapy: Clinical Practice, Challenges, and Future Perspectives
This session explores Switzerland’s pioneering limited medical use programme for psychedelic-assisted therapy, including LSD, psilocybin and MDMA. It examines the regulatory framework, clinical experience, patient selection and ethical considerations, as well as current developments and future challenges for policy and practice.
Helena Aicher, PhD
Psychotherapist (Psychiatric Clinic of the University of Zurich); Postdoctoral researcher (University of Zurich)
13:05–14:05
·
Lunch break
14:05–14:50
Beyond the Molecule: Access, Care Models, and the Future of Psychedelic Care in Europe
The talk explores the path from scientific evidence to equitable access to psychedelic therapies in Europe, including regulatory approvals, reimbursement, professional training and treatment models that go beyond the drug alone. It argues that psychedelic care depends not only on pharmacology, but also on context, relationship, preparation, integration and longer-term support. It also examines Europe’s innovation challenges and the need for a deliberate strategy that translates evidence into reimbursed, equitable and comprehensive care.
Tadeusz Hawrot
Founder and CEO (PAREA)
14:05–14:50
Beyond the Molecule: Access, Care Models, and the Future of Psychedelic Care in Europe
The talk explores the path from scientific evidence to equitable access to psychedelic therapies in Europe, including regulatory approvals, reimbursement, professional training and treatment models that go beyond the drug alone. It argues that psychedelic care depends not only on pharmacology, but also on context, relationship, preparation, integration and longer-term support. It also examines Europe’s innovation challenges and the need for a deliberate strategy that translates evidence into reimbursed, equitable and comprehensive care.
Tadeusz Hawrot
Founder and CEO (PAREA)
14:05–14:50
Beyond the Molecule: Access, Care Models, and the Future of Psychedelic Care in Europe
The talk explores the path from scientific evidence to equitable access to psychedelic therapies in Europe, including regulatory approvals, reimbursement, professional training and treatment models that go beyond the drug alone. It argues that psychedelic care depends not only on pharmacology, but also on context, relationship, preparation, integration and longer-term support. It also examines Europe’s innovation challenges and the need for a deliberate strategy that translates evidence into reimbursed, equitable and comprehensive care.
Tadeusz Hawrot
Founder and CEO (PAREA)
14:50–15:35
Panel discussion
TBA
14:50–15:35
Panel discussion
TBA
14:50–15:35
Vestlusring
TBA
15:35–15:45
·
Closing remarks
13:20–14:20
·
Closing remarks
15:35–15:45
·
Closing remarks
Afterglow
Afterglow
Networking event. More info TBA.
TAIP Foundation reserves the right to make changes to the programme.
Standard tickets are now on sale. Prices valid until September 7.
Group Discount
For groups of 3 to 5 participants, the ticket price is €169 per person (valid until 7 September).
Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega
info@sataip.ee
Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega
info@sataip.ee
Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega
info@sataip.ee